Antibiotics are known to cause severe cutaneous adverse reactions, such as the rare acute generalized exanthematous pustulosis (AGEP). Unlike Stevens-Johnson syndrome or toxic epidermal necrolysis, AGEP is rarely life-threatening. Systemic involvement is not typical, and if present usually coincides with a mild elevation of the hepatic enzymes and a decrease in renal function. Hence, AGEP is known to have a good prognosis and to be life-threatening only in elderly patients or patients with chronic diseases. Herein, we report a case of AGEP in a young healthy male leading to systemic inflammatory response syndrome and to treatment in an intensive care unit after being treated with 5 different antibiotics. Initial symptoms were not indicative for AGEP and the patient's course of disease led promptly to critical cardiorespiratory symptoms and systemic inflammatory response syndrome. We assume that the administration of the 5 different antibiotics resulted in type IV allergy as well as secondary infection with Enterococcus faecium and Staphylococcus aureus, while the underlying periodontitis also contributed to the severity of this case.

Hotz C, Valeyrie-Allanore L, Haddad C, Bouvresse S, Ortonne N, et al: Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol 2013;169:1223-1232.
Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, et al: Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008;58:33-40.
Sideroff A, Halevy S, Bouwes Bavinck JN, Vaillant L, Roujeau JC: Acute generalized exanthematous pustulosis (AGEP) - a clinical reaction pattern. J Cutan Pathol 2001;28:113-119.
Lin YV, Yang CH, Sindy H, Lin JY, Hui RCY, et al: Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis 2014;58:1377-1358.
Otero Rivas MM, Sanchez Sambucety P, Garcia-Ruiz de Morales JM, Pérez Paredes G, Rodriguez Prieto MA: Acute generalized exanthematous pustulosis due to dextromethorphan. Dermatol Online J 2013;19:10.
Hammerbeck AA, Daniels NH, Callen JP: Ioversol-induced acute generalized exanthematous pustulosis: a case report. Arch Dermatol 2009;145:683-687.
Kakeda M, Schlapbach C, Danelon G, Tang MM, Cecchinato V: Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. Arch Dermatol Res 2014;306:933-938.
Sideroff A, Dunant A, Viboud C, Halevy S, Bouwes Bavinck JS, et al: Risk factors for acute generalized exanthematous pustulosis (AGEP): results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007;157:989-996.
Hagiya H, Kimura M, Miyamoto, Haruki Y, Otsuka F: Acute generalized exanthematous pustulosis caused by daptomycin in a critically iII burn victim. Intern Med 2014;53:511-514.
Kumar R, Qureshi S, Jakus J, Palma-Diaz FM: A severe case of acute generalized exanthematous pustulosis (AGEP) in a child after the administration of amoxicillin-clavulanic acid: brief report. Pediatr Dermatol 2009;26:623-625.
Kostopoulos TC, Krishna SM, Brinster NK, Ortega-Loayza AG: Acute generalized exanthematous pustulosis: atypical presentations and outcomes. J Eur Acad Dermatol Venereol 2015;29:209-214.
Van Hattem S, Beerthuizen GI, Kardaun SH: Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP und TEN exist? Clinical report and review of the literature. Br J Dermatol 2014;171:1539-1545.
Wöhrl S: Clinical work-up of adverse drug reactions. Expert Rev Dermatol 2007;2:217-231.
Lesterhuis WJ, Tjioe M, Stumpenhausen GA, van Crevel R: Acute generalized exanthematous pustulosis mimicking septic shock. Am J Med 2005;116:574-575.
Bomarrito L, Zisa G, Delrosso G, Farinelli P, Galimberti M: A case of acute generalized exanthematous pustulosis due to amoxicillin-clavulanate with multiple positivity to beta-lactam patch testing. Eur Ann Allergy Clin Immunol 2013;45:178-180.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.